HSP990 (NVP-HSP990) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 477

Clinical Trials

Multiple clinical trials evaluate HSP990 across oncology and neurodegenerative disease indications. Early-stage Phase 1 dose-escalation studies sponsored by Novartis Pharmaceuticals previously investigated oral administration in patients with advanced solid malignancies, resulting in completed and terminated statuses. Furthermore, academic institutions, including Universitaire Ziekenhuizen KU Leuven, are currently recruiting participants for an observational study utilizing [11C]HSP990 as a novel PET radioligand to quantify brain Hsp90 in Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07380204	RECRUITING	Parkinson's Disease (PD); Alzheimer's Disease (AD); Amyotrophic Lateral Sclerosis (ALS)	Universitaire Ziekenhuizen KU Leuven	2024-09-04
NCT00879905	COMPLETED	Advanced Solid Malignancies	Novartis Pharmaceuticals	2009-05	PHASE1
NCT01064089	TERMINATED	Advanced Solid Tumors	Novartis Pharmaceuticals	2010-02	PHASE1
NCT00879905	Completed	Advanced Solid Malignancies	Novartis Pharmaceuticals\|Novartis	2009-05	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-02-02)

Check the HSP990 (NVP-HSP990) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

HSP990 selectively binds to heat shock protein 90 isoforms HSP90α and HSP90β, disrupting chaperone-mediated client protein folding and driving downstream cell cycle arrest and apoptosis. By inhibiting HSP90 activity, the compound prevents tumor cell proliferation in advanced solid malignancies and serves as a diagnostic target for evaluating chaperone dysregulation in neurodegenerative disorders such as Parkinson's and Alzheimer's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).